Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 6;77(13):1660-1669.
doi: 10.1016/j.jacc.2020.12.065. Epub 2021 Feb 23.

Therapeutic Potential of Ketone Bodies for Patients With Cardiovascular Disease: JACC State-of-the-Art Review

Affiliations
Free article
Review

Therapeutic Potential of Ketone Bodies for Patients With Cardiovascular Disease: JACC State-of-the-Art Review

Salva R Yurista et al. J Am Coll Cardiol. .
Free article

Abstract

Metabolic perturbations underlie a variety of cardiovascular disease states; yet, metabolic interventions to prevent or treat these disorders are sparse. Ketones carry a negative clinical stigma as they are involved in diabetic ketoacidosis. However, evidence from both experimental and clinical research has uncovered a protective role for ketones in cardiovascular disease. Although ketones may provide supplemental fuel for the energy-starved heart, their cardiovascular effects appear to extend far beyond cardiac energetics. Indeed, ketone bodies have been shown to influence a variety of cellular processes including gene transcription, inflammation and oxidative stress, endothelial function, cardiac remodeling, and cardiovascular risk factors. This paper reviews the bioenergetic and pleiotropic effects of ketone bodies that could potentially contribute to its cardiovascular benefits based on evidence from animal and human studies.

Keywords: cardiovascular disease; heart failure; ketones; pleiotropic effects.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures The UMCG, which employs Drs. Yurista, de Boer, and Westenbrink, has received research grants and/or fees from Abbott, AstraZeneca, Bristol Myers Squibb, Novartis, Novo Nordisk, and Roche. Dr. Chong is supported by a fellowship jointly awarded by the National Health & Medical Research Council (GNT1162356) and National Heart Foundation of Australia (102126). Dr. Kelly is supported by NIH R01 HL058493, HL128349, and HL151345; and has served as a scientific consultant for Pfizer, Amgen, and Janssen. Dr. de Boer is supported by the Netherlands Heart Foundation (CVON DOUBLE DOSE, grant 2020-8005, CVON SHE-PREDICTS-HF, grant 2017-21, and CVON RED-CVD, grant 2017-11) and the European Research Council (ERC CoG 818715, SECRETE-HF); and has received personal fees from Abbott, AstraZeneca, Novartis, and Roche. Dr. Westenbrink is supported by the Netherlands Organisation for Scientific Research (NWO VENI, grant 016.176.147) and the Netherlands Heart Foundation Senior Clinical Scientist Grant (2019T064) and CVON DOUBLE DOSE (grant 2020-8005). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Similar articles

Cited by

Publication types